A Spark Of Good News For Precision Oncology In Breast Cancer

In a trial of metastatic triple-negative breast cancer, AZD5363 significantly extended patients ’ overall survival from 12.6 to 19.1 months, vs. placebo, when given with chemotherapy.
Source: Forbes.com Healthcare News - Category: Pharmaceuticals Authors: Tags: NYSE:AZN Source Type: news